Financial Results | Johnson & Johnson 2025 Q3 Cumulative Revenue USD 69629.00 Million Net Income USD 21688.00 Million
Johnson & Johnson(JNJ) posted the Q3 of its 2025 financial results on 10/22/2025, reporting total revenue of USD 69629.00 million in the first three quarters, up 5.02% from USD 66301.00 million year over year, reporting net income of USD 21688.00 million in the first three quarters, up 103.93% from USD 10635.00 million year over year. The EPS is USD 9.01 in the first three quaters, compare with USD 4.42 last period.
[Detailed Data]
| Million USD | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Total Revenue | 23993.00 | 23743.00 | 21893.00 | 22520.00 |
| Cost of Sales | 7303.00 | 7628.00 | 7357.00 | 7128.00 |
| Gross Profit | 16690.00 | 16115.00 | 14536.00 | 15392.00 |
| Total Operating Expenses | 9612.00 | 9453.00 | 8209.00 | 11624.00 |
| Operating Income | 7078.00 | 6662.00 | 6327.00 | 3768.00 |
| Net Income | 5152.00 | 5537.00 | 10999.00 | 3431.00 |
| Net Income Attributable to Common Shareholders | 5152.00 | 5537.00 | 10999.00 | 3431.00 |
| EPS(USD) | 2.14 | 2.3 | 4.57 | 1.4251 |
[Company Profile]
Johnson & Johnson was incorporated in the State of New Jersey in 1887. Johnson & Johnson and its subsidiaries have engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company's primary focus is products related to human health and well-being. The Company is organized into two business segments: Innovative Medicine and MedTech.
Comentarios
Aún no hay comentarios